Technical Analysis for LUMO - Lumos Pharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 3.00 | -0.66% | -0.02 |
LUMO closed down 0.66 percent on Wednesday, May 8, 2024, on 45 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Earnings Movers | Other | -0.66% | |
| Overbought Stochastic | Strength | -0.66% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% |
| Alert | Time |
|---|---|
| Possible NR7 | about 14 hours ago |
| Possible Inside Day | about 14 hours ago |
| Gap Down Partially Closed | about 18 hours ago |
| Gap Down Closed | about 18 hours ago |
| Reversed from Down | about 18 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Genetic Diseases Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Genetic Diseases Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.55 |
| 52 Week Low | 2.41 |
| Average Volume | 27,892 |
| 200-Day Moving Average | 3.10 |
| 50-Day Moving Average | 2.83 |
| 20-Day Moving Average | 2.78 |
| 10-Day Moving Average | 2.92 |
| Average True Range | 0.16 |
| RSI (14) | 61.24 |
| ADX | 26.47 |
| +DI | 24.53 |
| -DI | 13.53 |
| Chandelier Exit (Long, 3 ATRs) | 2.59 |
| Chandelier Exit (Short, 3 ATRs) | 2.89 |
| Upper Bollinger Bands | 3.14 |
| Lower Bollinger Band | 2.41 |
| Percent B (%b) | 0.81 |
| BandWidth | 26.10 |
| MACD Line | 0.07 |
| MACD Signal Line | 0.03 |
| MACD Histogram | 0.0376 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.11 | ||||
| Resistance 3 (R3) | 3.10 | 3.07 | 3.09 | ||
| Resistance 2 (R2) | 3.07 | 3.04 | 3.07 | 3.08 | |
| Resistance 1 (R1) | 3.03 | 3.02 | 3.05 | 3.04 | 3.08 |
| Pivot Point | 3.00 | 3.00 | 3.01 | 3.00 | 3.00 |
| Support 1 (S1) | 2.96 | 2.97 | 2.98 | 2.97 | 2.92 |
| Support 2 (S2) | 2.93 | 2.95 | 2.93 | 2.92 | |
| Support 3 (S3) | 2.89 | 2.93 | 2.91 | ||
| Support 4 (S4) | 2.90 |
